JP2018538356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538356A5 JP2018538356A5 JP2018536700A JP2018536700A JP2018538356A5 JP 2018538356 A5 JP2018538356 A5 JP 2018538356A5 JP 2018536700 A JP2018536700 A JP 2018536700A JP 2018536700 A JP2018536700 A JP 2018536700A JP 2018538356 A5 JP2018538356 A5 JP 2018538356A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- igf
- mutations
- bispecific protein
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 108090000623 proteins and genes Proteins 0.000 claims 30
- 230000035772 mutation Effects 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 24
- 102000004121 Annexin A5 Human genes 0.000 claims 13
- 108090000672 Annexin A5 Proteins 0.000 claims 13
- 230000008685 targeting Effects 0.000 claims 12
- 210000001519 tissue Anatomy 0.000 claims 12
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 10
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 9
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 8
- 239000012190 activator Substances 0.000 claims 8
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 6
- 102000044162 human IGF1 Human genes 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 5
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 claims 4
- 210000000170 cell membrane Anatomy 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 102000054215 human ANXA5 Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000026731 phosphorylation Effects 0.000 claims 4
- 238000006366 phosphorylation reaction Methods 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 230000017423 tissue regeneration Effects 0.000 claims 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 2
- 108091008611 Protein Kinase B Proteins 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 101710150709 Serine/threonine-protein kinase B Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 230000009087 cell motility Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021159345A JP7365715B2 (ja) | 2015-10-02 | 2021-09-29 | 組織修復のための二重特異性治療用タンパク質 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236169P | 2015-10-02 | 2015-10-02 | |
| US62/236,169 | 2015-10-02 | ||
| US201562237889P | 2015-10-06 | 2015-10-06 | |
| US62/237,889 | 2015-10-06 | ||
| US201662322910P | 2016-04-15 | 2016-04-15 | |
| US62/322,910 | 2016-04-15 | ||
| PCT/US2016/054744 WO2017059231A1 (en) | 2015-10-02 | 2016-09-30 | Bi-specific therapeutic proteins for tissue repair |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021159345A Division JP7365715B2 (ja) | 2015-10-02 | 2021-09-29 | 組織修復のための二重特異性治療用タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538356A JP2018538356A (ja) | 2018-12-27 |
| JP2018538356A5 true JP2018538356A5 (enExample) | 2019-12-26 |
| JP7005019B2 JP7005019B2 (ja) | 2022-02-04 |
Family
ID=58427983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536700A Active JP7005019B2 (ja) | 2015-10-02 | 2016-09-30 | 組織修復のための二重特異性治療用タンパク質 |
| JP2021159345A Active JP7365715B2 (ja) | 2015-10-02 | 2021-09-29 | 組織修復のための二重特異性治療用タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021159345A Active JP7365715B2 (ja) | 2015-10-02 | 2021-09-29 | 組織修復のための二重特異性治療用タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US10040840B2 (enExample) |
| EP (2) | EP3865147B1 (enExample) |
| JP (2) | JP7005019B2 (enExample) |
| CN (2) | CN108367048B (enExample) |
| CA (1) | CA3000742A1 (enExample) |
| ES (1) | ES2863278T3 (enExample) |
| WO (1) | WO2017059231A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6200806B2 (ja) * | 2010-05-21 | 2017-09-20 | メリマック ファーマシューティカルズ インコーポレーティッド | 二重特異的融合タンパク質 |
| US10040840B2 (en) | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
| CN111763680A (zh) * | 2019-05-22 | 2020-10-13 | 杭州杰迪生物科技有限公司 | 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞 |
| JP7355326B2 (ja) * | 2019-08-05 | 2023-10-03 | デンカ株式会社 | 経粘膜投与薬剤 |
| AU2020343512A1 (en) * | 2019-09-06 | 2022-04-07 | Novartis Ag | Therapeutic fusion proteins |
| CN112584507B (zh) | 2019-09-30 | 2022-05-17 | 华为技术有限公司 | 一种数据处理方法、装置及存储介质 |
| WO2021133822A1 (en) | 2019-12-24 | 2021-07-01 | Juvena Therapeutics,Inc. | Regenerative polypeptides and uses thereof |
| CN111195350A (zh) * | 2020-01-15 | 2020-05-26 | 重庆大学 | IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用 |
| EP4188410B1 (en) * | 2020-07-30 | 2025-11-05 | Silver Creek Pharmaceuticals, Inc. | Chimeric proteins for use in the treatment of central nervous system disorders |
| CN117897399A (zh) | 2021-06-14 | 2024-04-16 | Inserm(法国国家健康医学研究院) | 突变的膜联蛋白a5多肽及其在治疗目的中的用途 |
| EP4359425A4 (en) | 2021-06-21 | 2025-04-09 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND THEIR USES |
| EP4363439A4 (en) * | 2021-06-30 | 2025-12-17 | Silver Creek Pharmaceuticals Inc | Chimeric proteins for the targeted release of growth factors to the glomerulus |
| WO2023159067A2 (en) * | 2022-02-15 | 2023-08-24 | Silver Creek Pharmaceuticals, Inc. | Chimeric proteins for treatment of acute radiation syndrome |
| WO2025207443A1 (en) * | 2024-03-25 | 2025-10-02 | Cavalry Biosciences, Inc. | Igf-1-related compositions and uses of the same |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL269416A (enExample) | 1960-09-21 | |||
| GB8819826D0 (en) | 1988-08-20 | 1988-09-21 | Kabivitrum Ab | Glycosylated igf-1 |
| US5679771A (en) | 1990-02-13 | 1997-10-21 | Gropep Pty. Ltd. | Method for treating intestinal diseases |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| US5632986A (en) | 1991-05-09 | 1997-05-27 | The University Of Washington | Phospholipid-targeted thrombolytic agents |
| US5444045A (en) * | 1992-09-17 | 1995-08-22 | Gropep, Pty. Ltd. | Method of administering IGF-1, IGF-2, and analogs thereof to birds |
| ATE237366T1 (de) * | 1994-01-24 | 2003-05-15 | Neorx Corp | Radioaktiv-markierte annexine |
| EP0756494A1 (en) | 1994-05-24 | 1997-02-05 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| CA2224859A1 (en) | 1996-04-17 | 1997-10-23 | Amitabh Gaur | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| CA2331789C (en) | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| US6387663B1 (en) | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| PT1141015E (pt) | 1999-01-06 | 2009-10-13 | Genentech Inc | Variantes mutantes do factor de crescimento do tipo insulina (igf)i |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2001007059A1 (en) | 1999-07-21 | 2001-02-01 | University Of Southern California | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| JP2001251104A (ja) | 2000-03-03 | 2001-09-14 | Murata Mfg Co Ltd | 非可逆回路素子及び通信機装置 |
| ATE463252T1 (de) | 2000-08-29 | 2010-04-15 | Aurogen Inc | Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf |
| AR032028A1 (es) | 2001-01-05 | 2003-10-22 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| ATE384736T1 (de) | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | Subzelluläres targeting von therapeutischen proteinen |
| US7049286B2 (en) | 2001-08-30 | 2006-05-23 | Diatos, S.A. | Insulin conjugates and methods of use thereof |
| AU2008200706B2 (en) | 2001-10-16 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US7576186B2 (en) | 2002-04-23 | 2009-08-18 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
| WO2003103577A2 (en) * | 2002-06-06 | 2003-12-18 | Tze Chein Wun | Novel recombinant anticoagulant proteins |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20040213738A1 (en) | 2003-03-31 | 2004-10-28 | Susan Croll-Kalish | CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity |
| WO2005033134A2 (en) | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Secreted protein therapeutics and uses thereof |
| BRPI0406606A (pt) | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| WO2005117973A2 (en) | 2004-05-05 | 2005-12-15 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| WO2006004910A2 (en) | 2004-06-28 | 2006-01-12 | Transtarget Inc. | Improved bispecific antibodies |
| US7511016B2 (en) | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| JP2008510732A (ja) | 2004-08-20 | 2008-04-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 心臓組織の損傷を処置、予防、阻害、または緩和する方法 |
| US7531318B2 (en) | 2004-08-20 | 2009-05-12 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
| EP1812082B1 (en) * | 2004-10-21 | 2013-08-14 | IGF Oncology, LLC | Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer |
| WO2006074390A2 (en) | 2005-01-07 | 2006-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides |
| JP2008526979A (ja) | 2005-01-14 | 2008-07-24 | サイトジェン コーポレーション | 抗ｐｓｍａ抗体による併用癌治療法 |
| DK1853631T3 (en) * | 2005-01-24 | 2016-03-29 | Univ Texas | Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF |
| WO2006091209A2 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| US7521211B2 (en) | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| EP1890722A2 (en) | 2005-05-27 | 2008-02-27 | Five Prime Therapeutics, Inc. | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
| KR20080071119A (ko) | 2005-08-12 | 2008-08-01 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| US8067357B2 (en) | 2005-12-12 | 2011-11-29 | Mosamedix B.V. | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
| US7776816B2 (en) | 2006-01-20 | 2010-08-17 | Board Of Regents, The University Of Texas System | Preserving hypoxic tissue |
| AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| US7951918B2 (en) | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| JO2968B1 (en) | 2006-06-09 | 2016-03-15 | نوفارتيس ايه جي | Polypeptides are a stable insulin-like growth factor |
| US9187517B2 (en) | 2006-11-13 | 2015-11-17 | The Brigham And Women's Hospital, Inc. | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
| SE0700218L (sv) | 2007-01-23 | 2008-02-26 | Teknikbolaget K Samuelsson Ab | Sprutmunstycksanordning för brandsläckningssystem |
| US8003761B2 (en) | 2007-01-23 | 2011-08-23 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US8889140B2 (en) | 2007-05-31 | 2014-11-18 | Transtarget, Inc. | Compositions and methods for tissue repair |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| WO2009030720A2 (en) | 2007-09-06 | 2009-03-12 | Novozymes Biopharma Dk A/S | Process for producing a recombinant protein |
| MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| EP2391630A2 (en) * | 2009-01-31 | 2011-12-07 | IGF Oncology, LLC | Anti-cancer protein-platinum conjugates |
| WO2011011071A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| JP5571186B2 (ja) | 2009-07-22 | 2014-08-13 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | ５９位にアミノ酸置換を有するインスリン様増殖因子−１（ｉｇｆ−１）の類似体 |
| CA2777242A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| MX2012004793A (es) | 2009-10-30 | 2012-07-20 | Novozymes Biopharma Dk As | Variantes de albumina. |
| JP6200806B2 (ja) | 2010-05-21 | 2017-09-20 | メリマック ファーマシューティカルズ インコーポレーティッド | 二重特異的融合タンパク質 |
| CN103354835B (zh) | 2010-12-08 | 2016-03-02 | 韦尔赛特公司 | 抑制人多能干细胞生长的试剂和方法 |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| CN104011070A (zh) | 2011-12-15 | 2014-08-27 | 爱德迪安（北京）生物技术有限公司 | 具有降血糖作用的化合物、组合物及其用途 |
| CN108383902A (zh) | 2012-09-26 | 2018-08-10 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
| BR112015024758A2 (pt) | 2013-03-29 | 2017-10-24 | Merrimack Pharmaceuticals Inc | proteínas de fusão de ligação à cartilagem |
| CA2936675C (en) | 2014-01-12 | 2023-06-27 | Igf Oncology, Llc | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
| US10040840B2 (en) | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
-
2016
- 2016-09-30 US US15/281,795 patent/US10040840B2/en active Active
- 2016-09-30 JP JP2018536700A patent/JP7005019B2/ja active Active
- 2016-09-30 WO PCT/US2016/054744 patent/WO2017059231A1/en not_active Ceased
- 2016-09-30 CN CN201680070850.6A patent/CN108367048B/zh active Active
- 2016-09-30 CA CA3000742A patent/CA3000742A1/en active Pending
- 2016-09-30 EP EP21152085.3A patent/EP3865147B1/en active Active
- 2016-09-30 CN CN202210868944.5A patent/CN115960249A/zh active Pending
- 2016-09-30 EP EP16852701.8A patent/EP3355907B1/en active Active
- 2016-09-30 ES ES16852701T patent/ES2863278T3/es active Active
-
2018
- 2018-07-03 US US16/026,319 patent/US10633425B2/en active Active
-
2020
- 2020-03-17 US US16/820,960 patent/US11155593B2/en active Active
-
2021
- 2021-09-28 US US17/487,120 patent/US11879002B2/en active Active
- 2021-09-29 JP JP2021159345A patent/JP7365715B2/ja active Active
-
2022
- 2022-02-10 US US17/668,825 patent/US12122819B2/en active Active
-
2024
- 2024-09-17 US US18/887,949 patent/US20250145682A1/en active Pending